Abstract
Sowmya Sekizar, Kristján Holt, Sharon Meyers, Makis Tzioras, Declan King, Jane Tulloch, Rosemary J. Jackson, Tara L. Spires‐Jones
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
europepmc
Confidence 96%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
10.64898/2026.05.09.26352797
10.64898/2026.05.09.26352797
Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report
10.1038/s41591-019-0611-3 · 2019
Oligomeric Aβ in the monkey brain impacts synaptic integrity and induces accelerated cortical aging
10.1073/pnas.1902301116 · 2019
Activation of mGluR1 mediates C1q-dependent microglial phagocytosis of glutamatergic synapses in Alzheimer’s rodent models
10.1007/s12035-019-1467-8 · 2019
Alzheimer brain-derived amyloid β-protein impairs synaptic remodeling and memory consolidation
10.1016/j.neurobiolaging.2012.10.028 · 2013
Staging of Alzheimer’s disease-related neurofibrillary changes
10.1016/0197-4580(95)00021-6 · 1995
ApoE3 R136S binds to tau and blocks its propagation, suppressing neurodegeneration in mice with Alzheimer’s disease
10.1016/j.neuron.2024.12.015 · 2025
APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spread
10.1016/j.cell.2023.11.029 · 2024
Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways
10.1038/nature12776 · 2013
Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes
10.1073/pnas.1609896113 · 2016
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
10.1038/ng0694-180 · 1994
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families
10.1126/science.8346443 · 1993
Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies
10.1016/j.neuron.2018.10.014 · 2018
Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity
10.1002/ana.410270502 · 1990
Animal models of atherosclerosis
10.1161/atvbaha.111.237693 · 2012
Comparative profiling of the synaptic proteome from Alzheimer’s disease patients with focus on the APOE genotype
10.1186/s40478-019-0847-7 · 2019
Complement and microglia mediate early synapse loss in Alzheimer mouse models
10.1126/science.aad8373 · 2016
Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of β-amyloidosis
10.1016/j.neuron.2017.11.014 · 2017
Clusterin accumulates in synapses in Alzheimer’s disease and is increased in apolipoprotein E4 carriers
10.1093/braincomms/fcz003 · 2019
Synaptic resilience is associated with maintained cognition during
2022
Apolipoprotein E4 effects in Alzheimer’s disease are mediated by synaptotoxic oligomeric amyloid-β
10.1093/brain/aws127 · 2012
Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques
10.1073/pnas.0811698106 · 2009
Astrocytes phagocytose adult hippocampal synapses for circuit homeostasis
10.1038/s41586-020-03060-3 · 2021
Microglia determine ß-amyloid plaque burden but are non-essential for downstream
2024
Apolipoprotein E metabolism and functions in brain and its role in Alzheimer’s disease
10.1097/mol.0000000000000383 · 2017
Neurotoxic reactive astrocytes are induced by activated microglia
10.1038/nature21029 · 2017
APOE4 causes widespread molecular and cellular alterations associated with Alzheimer’s disease phenotypes in human iPSC-derived brain cell types
10.1016/j.neuron.2018.05.008 · 2018
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
10.1038/nrneurol.2012.263 · 2013
Microglia-astrocyte crosstalk in the amyloid plaque niche of an Alzheimer’s disease mouse model, as revealed by spatial transcriptomics
10.1016/j.celrep.2024.114216 · 2024
Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-β
10.1016/j.nbd.2004.11.005 · 2005
The R136S mutation in the APOE3 gene confers resilience against tau pathology via inhibition of the cGAS-STING-IFN pathway
10.1016/j.immuni.2025.05.023 · 2025
The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation
10.1038/s41593-023-01480-8 · 2023
Amyloid precursor protein and endosomal‐lysosomal dysfunction in Alzheimer’s disease: inseparable partners in a multifactorial disease
10.1096/fj.201700359 · 2017
Typical development of synaptic and neuronal properties can proceed without microglia in the cortex and thalamus
10.1038/s41593-024-01833-x · 2025
Amyloid beta and tau cooperate to cause reversible behavioral and transcriptional deficits in a model of Alzheimer’s disease
10.1016/j.celrep.2019.11.044 · 2019
Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells
10.1073/pnas.89.10.4471 · 1992
Alterations in the brain lipidome of Alzheimer’s disease donors with rare TREM2 risk variants
10.1093/braincomms/fcaf452 · 2026
APOE3 Christchurch heterozygosity and autosomal dominant Alzheimer’s disease
10.1056/nejmoa2308583 · 2024
Local externalization of phosphatidylserine mediates developmental synaptic pruning by microglia
10.15252/embj.2020105380 · 2020
Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway
10.1523/jneurosci.4970-06.2007 · 2007
Astrocyte-derived interleukin-33 promotes microglial synapse engulfment and neural circuit development
10.1126/science.aal3589 · doi-reference
ApoE facilitates the microglial response to amyloid plaque pathology
10.1084/jem.20171265 · doi-reference
Synaptic degeneration in Alzheimer disease
10.1038/s41582-022-00749-z · doi-reference
Invited review: APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer’s disease
10.1111/nan.12529 · doi-reference
APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology
10.1186/s13024-024-00793-x · doi-reference
Protective mechanisms against Alzheimer’s disease in APOE3‐Christchurch homozygous astrocytes
10.1002/alz.70589 · doi-reference
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
10.1212/wnl.58.12.1791 · doi-reference
ApoE-dependent plasticity in Alzheimer’s disease
10.1385/jmn:23:3:167 · doi-reference
Physical basis of cognitive alterations in alzheimer’s disease: synapse loss is the major correlate of cognitive impairment
10.1002/ana.410300410 · doi-reference
The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system
10.1016/j.ajpath.2012.06.033 · doi-reference
Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q
10.1126/scitranslmed.abi8593 · doi-reference
Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease
10.1016/j.nbd.2008.10.011 · doi-reference
10.1038/nature24016
10.1038/nature24016 · doi-reference
Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice
10.1126/scitranslmed.aaf6295 · doi-reference
Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway
10.1523/jneurosci.4970-06.2007 · doi-reference
Local externalization of phosphatidylserine mediates developmental synaptic pruning by microglia
10.15252/embj.2020105380 · doi-reference
APOE3 Christchurch heterozygosity and autosomal dominant Alzheimer’s disease
10.1056/nejmoa2308583 · doi-reference
Alterations in the brain lipidome of Alzheimer’s disease donors with rare TREM2 risk variants
10.1093/braincomms/fcaf452 · doi-reference
Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells
10.1073/pnas.89.10.4471 · doi-reference
Amyloid beta and tau cooperate to cause reversible behavioral and transcriptional deficits in a model of Alzheimer’s disease
10.1016/j.celrep.2019.11.044 · doi-reference
Typical development of synaptic and neuronal properties can proceed without microglia in the cortex and thalamus
10.1038/s41593-024-01833-x · doi-reference
Amyloid precursor protein and endosomal‐lysosomal dysfunction in Alzheimer’s disease: inseparable partners in a multifactorial disease
10.1096/fj.201700359 · doi-reference
The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation
10.1038/s41593-023-01480-8 · doi-reference
The R136S mutation in the APOE3 gene confers resilience against tau pathology via inhibition of the cGAS-STING-IFN pathway
10.1016/j.immuni.2025.05.023 · doi-reference
Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-β
10.1016/j.nbd.2004.11.005 · doi-reference
Microglia-astrocyte crosstalk in the amyloid plaque niche of an Alzheimer’s disease mouse model, as revealed by spatial transcriptomics
10.1016/j.celrep.2024.114216 · doi-reference
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
10.1038/nrneurol.2012.263 · doi-reference
APOE4 causes widespread molecular and cellular alterations associated with Alzheimer’s disease phenotypes in human iPSC-derived brain cell types
10.1016/j.neuron.2018.05.008 · doi-reference
Neurotoxic reactive astrocytes are induced by activated microglia
10.1038/nature21029 · doi-reference
Apolipoprotein E metabolism and functions in brain and its role in Alzheimer’s disease
10.1097/mol.0000000000000383 · doi-reference
Astrocytes phagocytose adult hippocampal synapses for circuit homeostasis
10.1038/s41586-020-03060-3 · doi-reference
Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques
10.1073/pnas.0811698106 · doi-reference
Apolipoprotein E4 effects in Alzheimer’s disease are mediated by synaptotoxic oligomeric amyloid-β
10.1093/brain/aws127 · doi-reference
Clusterin accumulates in synapses in Alzheimer’s disease and is increased in apolipoprotein E4 carriers
10.1093/braincomms/fcz003 · doi-reference
Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of β-amyloidosis
10.1016/j.neuron.2017.11.014 · doi-reference
Complement and microglia mediate early synapse loss in Alzheimer mouse models
10.1126/science.aad8373 · doi-reference
Comparative profiling of the synaptic proteome from Alzheimer’s disease patients with focus on the APOE genotype
10.1186/s40478-019-0847-7 · doi-reference
Animal models of atherosclerosis
10.1161/atvbaha.111.237693 · doi-reference
Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity
10.1002/ana.410270502 · doi-reference
Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies
10.1016/j.neuron.2018.10.014 · doi-reference